CU22740A1 - Formulación de ácidos nucleicos y acemanano - Google Patents

Formulación de ácidos nucleicos y acemanano

Info

Publication number
CU22740A1
CU22740A1 CU1998126A CU1998126A CU22740A1 CU 22740 A1 CU22740 A1 CU 22740A1 CU 1998126 A CU1998126 A CU 1998126A CU 1998126 A CU1998126 A CU 1998126A CU 22740 A1 CU22740 A1 CU 22740A1
Authority
CU
Cuba
Prior art keywords
formulations
formulation
vaccine
acemanano
nucleic acid
Prior art date
Application number
CU1998126A
Other languages
English (en)
Inventor
Lasa Alexis Musacchio
Menendez Lissete Crombet
Vazquez Diogenes Quintana
Oquendo Belquis Sandez
Buch Antonieta Herrera
Perez Enrique Iglesias
Diaz Dagmara Pichardo
Rubido Julio Cesar Aguilar
Angulo Maria De Jesus Leal
Nieto Gerardo Enrique Guillen
Gonzalez Verena Lucila Muzio
Arias Eduardo Penton
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU1998126A priority Critical patent/CU22740A1/es
Priority to US09/530,925 priority patent/US6358933B1/en
Priority to BR9906761-7A priority patent/BR9906761A/pt
Priority to EP99942707A priority patent/EP1029549B1/en
Priority to DE69923829T priority patent/DE69923829D1/de
Priority to CA002308444A priority patent/CA2308444A1/en
Priority to AT99942707T priority patent/ATE289518T1/de
Priority to PCT/CU1999/000004 priority patent/WO2000013704A1/es
Priority to CN99801915A priority patent/CN1287493A/zh
Priority to ARP990104496A priority patent/AR020403A1/es
Publication of CU22740A1 publication Critical patent/CU22740A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención está relacionada con la rama de la medicina, particularmente con el uso de nuevas formulaciones de adyuvantes con antígenos vacunales. El objetivo técnico que se persigue con la invención propuesta es, precisamente, el desarrollo de formulaciones capaces de potenciar la respuesta inmune del organismo a vacunas de ácidos nucleicos. Para lograr este objetivo se desarrolló una formulación que contiene como componentes fundamentales al ácido nucleico vacunal y al acemanano en proporciones adecuadas, además de estabilizadores y preservo. Las formulaciones de esta invención son aplicables en la industria farmacéutica como formulaciones vacunales tanto para uso humano como veterinario.
CU1998126A 1998-09-07 1998-09-07 Formulación de ácidos nucleicos y acemanano CU22740A1 (es)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CU1998126A CU22740A1 (es) 1998-09-07 1998-09-07 Formulación de ácidos nucleicos y acemanano
US09/530,925 US6358933B1 (en) 1998-09-07 1999-09-03 Formulation of nucleic acid and acemannan
BR9906761-7A BR9906761A (pt) 1998-09-07 1999-09-03 Formulação de vacina de ácidos nucleicos e acemanano.
EP99942707A EP1029549B1 (en) 1998-09-07 1999-09-03 Formulation of nucleic acids and acemannan
DE69923829T DE69923829D1 (de) 1998-09-07 1999-09-03 Zusammensetzung von nucleinsäuren und acemannan
CA002308444A CA2308444A1 (en) 1998-09-07 1999-09-03 Formulation of nucleic acids and acemannan
AT99942707T ATE289518T1 (de) 1998-09-07 1999-09-03 Zusammensetzung von nucleinsäuren und acemannan
PCT/CU1999/000004 WO2000013704A1 (es) 1998-09-07 1999-09-03 Formulacion de acidos nucleicos y acemanano
CN99801915A CN1287493A (zh) 1998-09-07 1999-09-03 含核酸和醋孟南的制剂
ARP990104496A AR020403A1 (es) 1998-09-07 1999-09-07 Formulacion de acidos nucleicos y acemanano

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU1998126A CU22740A1 (es) 1998-09-07 1998-09-07 Formulación de ácidos nucleicos y acemanano

Publications (1)

Publication Number Publication Date
CU22740A1 true CU22740A1 (es) 2002-02-28

Family

ID=5459419

Family Applications (1)

Application Number Title Priority Date Filing Date
CU1998126A CU22740A1 (es) 1998-09-07 1998-09-07 Formulación de ácidos nucleicos y acemanano

Country Status (10)

Country Link
US (1) US6358933B1 (es)
EP (1) EP1029549B1 (es)
CN (1) CN1287493A (es)
AR (1) AR020403A1 (es)
AT (1) ATE289518T1 (es)
BR (1) BR9906761A (es)
CA (1) CA2308444A1 (es)
CU (1) CU22740A1 (es)
DE (1) DE69923829D1 (es)
WO (1) WO2000013704A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223739B1 (en) 1995-06-07 2007-05-29 Powderject Vaccines, Inc. Adjuvanted genetic vaccines
WO2000047227A2 (en) 1999-02-09 2000-08-17 Powderject Vaccines, Inc. Mycobacterium tuberculosis, immunization
PT1913957E (pt) * 1999-11-03 2010-05-05 Powderject Vaccines Inc Vacinas genéticas adjuvantes
WO2004006837A2 (en) * 2002-07-12 2004-01-22 The Johns Hopkins University Mesothelin vaccines and model systems
US20090110702A1 (en) 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106616A (en) * 1988-01-14 1992-04-21 Carrington Laboratories, Inc. Administration of acemannan
IL104382A0 (en) * 1992-01-17 1993-05-13 Solvay Animal Health Inc Vaccine containing acemannan as an adjuvant

Also Published As

Publication number Publication date
WO2000013704A1 (es) 2000-03-16
DE69923829D1 (de) 2005-03-31
EP1029549B1 (en) 2005-02-23
AR020403A1 (es) 2002-05-08
ATE289518T1 (de) 2005-03-15
CA2308444A1 (en) 2000-03-16
US6358933B1 (en) 2002-03-19
EP1029549A1 (en) 2000-08-23
BR9906761A (pt) 2000-10-03
CN1287493A (zh) 2001-03-14

Similar Documents

Publication Publication Date Title
ES2157447T3 (es) Composicion de vacuna que comprende un antigeno de polisacarido conjugado adsorbido en fosfato de aluminio.
AR053680A1 (es) Composicion
BR0113822A (pt) Vacina
ES2147294T3 (es) Compuestos terapeuticos.
WO2015149944A3 (en) Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
ES2069435T3 (es) Composicion de vacuna para vacunar animales, en concreto mamiferos y mas concretamente cerdos o cochinos.
AR032597A1 (es) Uso de antigenos del virus de la gripe inactivado, en la preparacion de vacunas de una sola dosis intranasal; metodo para la profilaxis de enfermedades o de infecciones gripales en pacientes; equipos que comprenden dichas vacunas en dosis unicas y metodo para fabricar vacunas para la gripe para apli
HUP0101580A2 (hu) Gélesedő gyógyászati készítmények
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
ES2164251T3 (es) Vacuna que comprende un conjugado antigeno polisacarido-proteina transportadora y proteina transportadora libre.
BRPI0208183B8 (pt) peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer
AR035586A1 (es) Composicion de vacuna, equipo, metodos para incrementar la respuesta inmune, uso de un derivado de 1h-imidazo(4,5-c)quinolin-4-amina en la fabricacion de un medicamento, y combinacion de componentes para la administracion separada, secuencial o concomitante para el uso en la vacunacion de adn
BR9909915A (pt) Composições adjuvantes
AR041880A1 (es) Composicion inmunogena
BRPI0513460A (pt) composição aquosa suave apropriada para a limpeza do cabelo e da pele
AR014946A1 (es) UNA PROTEINA O FRAGMENTO DE PROTEINA, PROCEDIMIENTO DE PREPARACIoN, COMPOSICION TERAPEUTICA, COMPOSICION FARMACEUTICA Y VACUNA
ES2027005T3 (es) Procedimiento para preparar una formulacion farmaceutica de liberacion controlada de acrivastina.
CU22871A1 (es) Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
CU22740A1 (es) Formulación de ácidos nucleicos y acemanano
AR071741A1 (es) Vacunas contra la malaria
ES379641A1 (es) Procedimiento de produccion de antigenos inactivos para preparados farmaceuticos.
ES2039267T3 (es) Dihidropiridinamidas, procedimiento para su preparacion y su empleo en medicamentos.
BR0015597A (pt) Uso de anticorpos como vacinas
BR112016012435A8 (pt) vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2
BR112015013625A2 (pt) adjuvante de vacinação, preparação e vacinas contendo o mesmo